Nurix Therapeutics (NASDAQ:NRIX) Earns Overweight Rating from Analysts at Stephens

Analysts at Stephens assumed coverage on shares of Nurix Therapeutics (NASDAQ:NRIXGet Free Report) in a note issued to investors on Tuesday, Benzinga reports. The firm set an “overweight” rating and a $20.00 price target on the stock. Stephens’ price target points to a potential upside of 43.47% from the stock’s current price.

Several other brokerages have also recently weighed in on NRIX. Robert W. Baird upped their price target on Nurix Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a research note on Thursday, April 11th. Needham & Company LLC reissued a “buy” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, April 9th. Morgan Stanley increased their price objective on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a research report on Monday, February 26th. HC Wainwright reduced their price target on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. Finally, Wells Fargo & Company lowered their price objective on Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Friday, February 16th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.14.

View Our Latest Analysis on NRIX

Nurix Therapeutics Stock Up 3.2 %

Nurix Therapeutics stock opened at $13.94 on Tuesday. The company has a market capitalization of $685.15 million, a PE ratio of -5.24 and a beta of 2.10. The firm has a fifty day simple moving average of $14.03 and a two-hundred day simple moving average of $10.37. Nurix Therapeutics has a twelve month low of $4.22 and a twelve month high of $18.12.

Nurix Therapeutics (NASDAQ:NRIXGet Free Report) last released its quarterly earnings results on Wednesday, April 10th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.04. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. The business had revenue of $16.59 million during the quarter, compared to analyst estimates of $14.58 million. As a group, equities analysts expect that Nurix Therapeutics will post -3.15 earnings per share for the current fiscal year.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 6,812 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $10.02, for a total value of $68,256.24. Following the completion of the transaction, the chief financial officer now directly owns 68,333 shares of the company’s stock, valued at $684,696.66. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last three months, insiders sold 13,705 shares of company stock valued at $154,012. Insiders own 9.80% of the company’s stock.

Institutional Investors Weigh In On Nurix Therapeutics

Several institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its position in Nurix Therapeutics by 351.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock worth $58,000 after buying an additional 4,367 shares during the last quarter. Quest Partners LLC bought a new stake in Nurix Therapeutics in the fourth quarter worth about $59,000. Principal Financial Group Inc. boosted its position in shares of Nurix Therapeutics by 14.8% during the third quarter. Principal Financial Group Inc. now owns 15,531 shares of the company’s stock valued at $122,000 after buying an additional 2,002 shares during the period. Jump Financial LLC bought a new position in shares of Nurix Therapeutics during the fourth quarter valued at approximately $158,000. Finally, SG Americas Securities LLC bought a new stake in shares of Nurix Therapeutics during the 3rd quarter worth approximately $162,000.

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Featured Articles

Analyst Recommendations for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.